Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAIV in COPD Exacerbation Phenotypes
NCT04901455Phase 1Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Oct 2022
- Primary completion
- Feb 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of live attenuated influenza vaccine in influenza (3 arms), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Difference in mucosal immune response at Day 3. Started Oct 2022; status: completed.
02
Drugs
live attenuated influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT04901455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04901455.